ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)

Size: px
Start display at page:

Download "ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)"

Transcription

1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2016 ARIAD Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) 26 Landsdowne Street, Cambridge, Massachusetts (Address of principal executive offices) (Zip Code) Registrant s telephone number, including area code: (617) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR ) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR e-4(c))

2 ITEM 5.02 (b) and (c) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 8, 2016, the Board of Directors (the Board ) of ARIAD Pharmaceuticals, Inc. ( ARIAD or the Company ) appointed Manmeet S. Soni as the Company s Executive Vice President, Chief Financial Officer and Treasurer, effective March 21, 2016 (the Effective Date ), making him the Company s principal financial and accounting officer. Mr. Soni will succeed Edward M. Fitzgerald, who will be stepping down as the Company s Chief Financial Officer as of the Effective Date but will remain with the Company to ensure a seamless transition. Mr. Soni, age 38, most recently served as chief financial officer of Pharmacyclics, Inc., a biopharmaceutical company, where he was responsible for all finance, procurement, information technology and human resources functions, and played a vital role in Pharmacyclics acquisition by AbbVie, Inc. in May He first joined Pharmacyclics in September 2012 as corporate controller and executive director of finance, and was promoted to vice president, corporate controller in February 2013; senior vice president, finance in August 2013; and executive vice president, finance in November 2013, prior to being appointed as chief financial officer and treasurer in February Previously, Mr. Soni worked at ZELTIQ Aesthetics Inc. from January 2012 to September 2012, where he served as controller, senior director of finance, and was responsible for accounting, SEC and treasury functions. Prior to ZELTIQ, Mr. Soni worked at PricewaterhouseCoopers in San Jose, CA from June 2007 to January 2012 in the Life Science and Venture Capital Group, providing audit and assurance services to various public and privately held companies in the pharmaceutical, biotechnology, software and semiconductor space. Prior to that, he worked at PricewaterhouseCoopers, India providing audit and assurance services. Mr. Soni currently serves on the board of directors of Genoscience Pharma, a privately held biopharmaceutical company focused on developing a new family of compounds targeting cancer stem cells to offer an alternative to existing cancer treatments. He graduated from Hansraj College at Delhi University in India and is a Certified Public Accountant, licensed in the state of California. He also completed his Chartered Accountancy from the Institute of Chartered Accountants of India Employment Agreement On March 9, 2016, the Company entered into an executive employment agreement (the Employment Agreement ) with Mr. Soni that provides for an annual base salary of $475,000, an annual target bonus of 50 % of his annual base salary and a one-time relocation payment of $100,000. This relocation payment is subject to clawback in the event that Mr. Soni terminates his employment within the first two years of employment other than on account of an uncured material breach of the Employment Agreement by the Company or the Company terminates his employment for cause (as defined in the Employment Agreement) at any time. The Employment Agreement also provides for relocation and other employee benefits, and has a three-year term. In addition, the Employment Agreement provides for a grant of 150,000 performance-based share units ( PSUs ) and 550,000 stock options to Mr. Soni as inducement grants in accordance with NASDAQ Listing Rule 5635(c)(4). A percentage of the PSUs, ranging from 0 to 160%, will be earned based upon the relative total shareholder return ( TSR ) of the Company s stock price compared to the NASDAQ Biotechnology Index over a three year period ending December 31, The stock options will have an exercise price equal to the closing price of the Company s common stock on the date of grant and have a ten-year term. One-fourth of the stock options will vest on the first anniversary of their grant date, and the remaining portion of the stock options will vest in thirty-six approximately equal installments on a monthly basis thereafter. The vesting of the stock options and the PSUs are subject to Mr. Soni s continued employment, except as otherwise described in the Employment Agreement. In the event that the Company terminates Mr. Soni s employment during the term of the agreement without cause (as defined in the Employment Agreement) prior to or more than two years following a change in control of the Company, Mr. Soni will be entitled to receive his then-current salary for a period of 12 months following termination, and 12 months of continued coverage under the Company s group health insurance plan. In addition, the unvested portion of any outstanding equity-based incentive compensation awards that, absent such termination, would have vested in accordance with their terms during the remaining term of the agreement will vest. In the event that, within two years following or six months prior to a change in control of the Company, either the Company terminates Mr. Soni s employment without cause or Mr. Soni terminates his employment for good reason (as defined in the Employment Agreement), Mr. Soni will be entitled to receive his then-current salary for a period of 24 months following termination, and 18 months of continued coverage under the Company s group health insurance plan. In addition, any outstanding equity-based incentive compensation awards will vest and, if applicable, remain fully exercisable through their original term.

3 The severance benefits described above are subject to Mr. Soni s execution of a release of claims against the Company. In addition, the Employment Agreement requires Mr. Soni to comply with certain restrictive covenants following the termination of his employment. There are no family relationships between Mr. Soni and any director or executive officer of the Company that are required to be disclosed pursuant to Item 401(d) of Regulation S-K. There are no related party transactions involving the Company that are required to be disclosed pursuant to Item 404(a) of Regulation S-K related to Mr. Soni. The foregoing is only a summary of the Employment Agreement and is qualified in its entirety by reference to the Employment Agreement, the form of Performance Share Unit Agreement and the form of Stock Option Agreement, which the Company intends to file as exhibits to its Quarterly Report on Form 10-Q for the quarter ending March 31, Review of Board Membership and Structure As previously reported in the Company s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, the Company is currently conducting a company-wide, strategic review of the Company s operations aimed at increasing shareholder value. As part of this review, the Board has unanimously authorized Alexander J. Denner, Chairman of the Board, and Paris Panayiotopoulos, President, Chief Executive Officer and member of the Board, to evaluate the size, composition and organization of the Board, including whether to reconstitute the membership of the Board and/or to eliminate the classified board structure. In order to facilitate such evaluation and a potential reconstitution and/or declassification of the Board, each of the Company s directors tendered his or her conditional resignation from the Board (each, a Conditional Resignation ). Each Conditional Resignation provides that if any director is not selected to serve on the reconstituted Board, such director will resign from the Board effective as of the Company s 2016 annual meeting of stockholders. Further, with respect to any Class 3 director with a term expiring at the Company s 2018 annual meeting of stockholders, each Conditional Resignation provides further that if the Board approves an amendment to the Company s certificate of incorporation to effect a declassification of the Board, which amendment is approved by the Company s stockholders at the 2016 annual meeting of stockholders, such director will resign from the Board effective as of the date immediately prior to the 2017 annual meeting of stockholders. ITEM 8.01 Other Events. On March 11, 2016, the Company issued a press release announcing the appointment of Mr. Soni as the Company s Chief Financial Officer. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. ITEM 9.01 (d) Exhibit Exhibits. Financial Statements and Exhibits. Description 99.1 Press release dated March 11, 2016 The press release may contain hypertext links to information on our websites. The information on our websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.

4 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 14, 2016 ARIAD Pharmaceuticals, Inc. By: /s/ Thomas J. DesRosier. Thomas J. DesRosier, Esq. Executive Vice President, Chief Legal and Administrative Officer and Secretary

5 Exhibit List Exhibit Description 99.1 Press release dated March 11, 2016

6 Exhibit 99.1 News Release ARIAD ANNOUNCES APPOINTMENT OF MANMEET S. SONI AS CHIEF FINANCIAL OFFICER Cambridge, MA, March 11, 2016 ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Manmeet S. Soni, 38, as executive vice president, chief financial officer and treasurer, effective March 21, He will report to Paris Panayiotopoulos, president and chief executive officer of ARIAD. Mr. Soni will succeed Edward M. Fitzgerald, who has made significant contributions to the company as ARIAD s chief financial officer since Mr. Fitzgerald will work closely with Mr. Soni to ensure a seamless transition. I am delighted that Manmeet will be joining ARIAD as our Chief Financial Officer, stated Paris Panayiotopoulos, president and chief executive officer of ARIAD. Manmeet brings to ARIAD proven finance and transaction expertise and will play a critical role in completing our strategic review to further strengthen our position as a leading orphan oncology company. We welcome Manmeet to ARIAD and look forward to working with him. Mr. Soni most recently served as Chief Financial Officer of Pharmacyclics, Inc., a biopharmaceutical company, where he was responsible for all finance, procurement, information technology and human resources functions, and where he played a vital role in the acquisition of Pharmacyclics by AbbVie, Inc. in May Previously, Mr. Soni worked at ZELTIQ Aesthetics Inc., where he served as controller and senior director of finance, and where he was responsible for accounting, SEC and Treasury functions. Prior to ZELTIQ, Mr. Soni worked at PricewaterhouseCoopers San Jose, in the Life Science and Venture Capital Group, providing audit and assurance services to various public and privately held companies in the pharmaceutical, biotechnology, software and semiconductor space. Prior to that, he worked at PricewaterhouseCoopers, India providing audit and assurance services. I am very pleased about this opportunity to join the talented and passionate team at ARIAD, a company focused on making a difference in the lives of cancer patients with breakthrough medicines, said Mr. Soni. I look forward to working with Paris and the rest of the team in developing and executing on ARIAD s corporate strategy, while concentrating on building long-term value for shareholders. Mr. Panayiotopoulos added, On behalf of the company s Board of Directors, management team and employees, I want to thank Ed for his tremendous contributions to ARIAD, especially his leadership in building the financial and operational infrastructure as the company transitioned from its original focus on research and development into a fully integrated orphan oncology company. Mr. Soni currently serves on the board of Genoscience Pharma. He graduated from Hansraj College at Delhi University in India. He is a Certified Public Accountant, licensed in the State of California. He also completed his Chartered Accountancy from the Institute of Chartered Accountant of India. About ARIAD ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough

7 medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-totreat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit or follow ARIAD on Twitter Forward-Looking Statements This press release contains forward-looking statements, each of which are qualified in their entirety by this cautionary statement. Any statements contained herein which do not describe historical facts, including, but not limited to, the statements made by Messrs. Panayiotopoulos and Soni, are forward-looking statements that are based on management s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to, our ongoing strategic review, our ability to successfully commercialize and generate profits from sales of Iclusig and our product candidates, if approved; competition from alternative therapies; our ability to meet anticipated clinical trial commencement, enrollment and completion dates and regulatory filing dates for our products and product candidates and to move new development candidates into the clinic; our ability to execute on our key corporate initiatives; regulatory developments and safety issues, including difficulties or delays in obtaining regulatory and pricing and reimbursement approvals to market our products; our reliance on the performance of third-party manufacturers and specialty pharmacies for the supply and distribution of our products and product candidates; the occurrence of adverse safety events with our products and product candidates; the costs associated with our research, development, manufacturing, commercialization and other activities; the conduct, timing and results of preclinical and clinical studies of our products and product candidates, including that preclinical data and early-stage clinical data may not be replicated in later-stage clinical studies; the adequacy of our capital resources and the availability of additional funding; the ability to satisfy our contractual obligations, including under our leases, convertible debt and royalty financing agreements; patent protection and third-party intellectual property claims; litigation; our operations in foreign countries; risks related to key employees, markets, economic conditions, health care reform, prices and reimbursement rates; and other risk factors detailed in our public filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. CONTACTS: For Investors For Media Maria Cantor Liza Heapes (617) (617) # # #

IDEXX LABORATORIES, INC.

IDEXX LABORATORIES, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event

More information

ANALOG DEVICES INC FORM 8-K. (Current report filing) Filed 06/18/15 for the Period Ending 06/17/15

ANALOG DEVICES INC FORM 8-K. (Current report filing) Filed 06/18/15 for the Period Ending 06/17/15 ANALOG DEVICES INC FORM 8-K (Current report filing) Filed 06/18/15 for the Period Ending 06/17/15 Address ONE TECHNOLOGY WAY NORWOOD, MA 02062 Telephone 7813294700 CIK 0000006281 Symbol ADI SIC Code 3674

More information

SORRENTO THERAPEUTICS, INC.

SORRENTO THERAPEUTICS, INC. ˆ200F@WVSVmdG1Yng+Š 200F@WVSVmdG1Yng+ AZ0151AC599817 11.3.10 SWRvelaj0nb 31-Jul-2013 16:51 EST 577580 TX 1 3* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 CURRENT REPORT Pursuant

More information

CERIDIAN CORPORATION

CERIDIAN CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

FEDERAL DEPOSIT INSURANCE CORPORATION Washington, D.C. 20429 FORM 8-K. Summit State Bank (Exact name of registrant as specified in its charter)

FEDERAL DEPOSIT INSURANCE CORPORATION Washington, D.C. 20429 FORM 8-K. Summit State Bank (Exact name of registrant as specified in its charter) FEDERAL DEPOSIT INSURANCE CORPORATION Washington, D.C. 20429 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) the Securities Exchange Act 1934 Date Report (Date Earliest Event Reported):

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K ABBVIE INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K ABBVIE INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

RAYTHEON COMPANY (Exact name of registrant as specified in its charter)

RAYTHEON COMPANY (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 Date of Report (Date of earliest

More information

UNITED THERAPEUTICS CORP

UNITED THERAPEUTICS CORP UNITED THERAPEUTICS CORP FORM 8-K (Current report filing) Filed 11/13/14 for the Period Ending 11/11/14 Address 1040 SPRING ST SILVER SPRING, MD 20910 Telephone 3016089292 CIK 0001082554 Symbol UTHR SIC

More information

Learning Tree International, Inc.

Learning Tree International, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

Cellular Biomedicine Group, Inc.

Cellular Biomedicine Group, Inc. SECURITIES & EXCHANGE COMMISSION EDGAR FILING Cellular Biomedicine Group, Inc. Form: 8-K Date Filed: 2014-07-31 Corporate Issuer CIK: 1378624 Symbol: CBMG SIC Code: 2836 Copyright 2014, Issuer Direct Corporation.

More information

ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)

ACTINIUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

CNA FINANCIAL CORPORATION

CNA FINANCIAL CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

FEDERAL DEPOSIT INSURANCE CORPORATION. Washington, D.C. 20429 FORM 8-K CURRENT REPORT. PURSUANT TO SECTION 13 OR 15(d)

FEDERAL DEPOSIT INSURANCE CORPORATION. Washington, D.C. 20429 FORM 8-K CURRENT REPORT. PURSUANT TO SECTION 13 OR 15(d) FEDERAL DEPOSIT INSURANCE CORPORATION Washington, D.C. 20429 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):

More information

JER INVESTORS TRUST INC (JERT) 8-K. Current report filing Filed on 01/29/2009 Filed Period 01/28/2009

JER INVESTORS TRUST INC (JERT) 8-K. Current report filing Filed on 01/29/2009 Filed Period 01/28/2009 JER INVESTORS TRUST INC (JERT) 8-K Current report filing Filed on 01/29/2009 Filed Period 01/28/2009 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant

More information

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):

More information

APPLE INC FORM 8-K. (Current report filing) Filed 06/06/14 for the Period Ending 06/06/14

APPLE INC FORM 8-K. (Current report filing) Filed 06/06/14 for the Period Ending 06/06/14 APPLE INC FORM 8-K (Current report filing) Filed 06/06/14 for the Period Ending 06/06/14 Address ONE INFINITE LOOP CUPERTINO, CA 95014 Telephone (408) 996-1010 CIK 0000320193 Symbol AAPL SIC Code 3571

More information

Attached as Exhibit 99.1 is a copy of the press release relating to the appointment of Mr. Wollney to the Board.

Attached as Exhibit 99.1 is a copy of the press release relating to the appointment of Mr. Wollney to the Board. PIH 8-K 3/30/2015 Section 1: 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A AMENDMENT #1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A AMENDMENT #1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A AMENDMENT #1 CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date

More information

Delaware 000-50703 14-1839426 (State or other jurisdiction of incorporation)

Delaware 000-50703 14-1839426 (State or other jurisdiction of incorporation) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 16, 2014 (Date

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

NEVRO CORP FORM 8-K. (Current report filing) Filed 04/09/15 for the Period Ending 04/09/15

NEVRO CORP FORM 8-K. (Current report filing) Filed 04/09/15 for the Period Ending 04/09/15 NEVRO CORP FORM 8-K (Current report filing) Filed 04/09/15 for the Period Ending 04/09/15 Address 4040 CAMPBELL AVENUE SUITE 210 MENLO PARK, CA 94025 Telephone 650-251-0005 CIK 0001444380 Symbol NVRO SIC

More information

P. H. Glatfelter Company (Exact name of registrant as specified in its charter)

P. H. Glatfelter Company (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event

More information

BOOZ ALLEN HAMILTON HOLDING CORP

BOOZ ALLEN HAMILTON HOLDING CORP BOOZ ALLEN HAMILTON HOLDING CORP FORM 8-K (Current report filing) Filed 01/31/14 for the Period Ending 01/31/14 Address 8283 GREENSBORO DRIVE MCLEAN, VA 22102 Telephone 703-902-5000 CIK 0001443646 Symbol

More information

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported):

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 13, 2012 Date

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest

More information

NORTHROP GRUMMAN CORP /DE/

NORTHROP GRUMMAN CORP /DE/ NORTHROP GRUMMAN CORP /DE/ FORM 8-K (Current report filing) Filed 02/07/13 for the Period Ending 02/06/13 Address 2980 FAIRVIEW PARK DRIVE C/O NORTHROP GRUMMAN CORP FALLS CHURCH, VA 22042 Telephone 703-280-2900

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

FORUM ENERGY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter)

FORUM ENERGY TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

GSV CAPITAL CORP. FORM 8-K. (Current report filing) Filed 04/28/15 for the Period Ending 04/28/15

GSV CAPITAL CORP. FORM 8-K. (Current report filing) Filed 04/28/15 for the Period Ending 04/28/15 GSV CAPITAL CORP. FORM 8-K (Current report filing) Filed 04/28/15 for the Period Ending 04/28/15 Address 2925 WOODSIDE ROAD WOODSIDE, CA 94062 Telephone (650) 235-4777 CIK 0001509470 Symbol GSVC Industry

More information

PACIFIC ETHANOL, INC. (Exact name of registrant as specified in its charter)

PACIFIC ETHANOL, INC. (Exact name of registrant as specified in its charter) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported)

More information

For personal use only

For personal use only UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 15, 2012 Date of Report (Date

More information

SPHERIX INCORPORATED (Exact name of registrant as specified in its charter)

SPHERIX INCORPORATED (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

FEDERAL DEPOSIT INSURANCE CORPORATION. Washington, D.C FORM 8-K CURRENT REPORT. PURSUANT TO SECTION 13 OR 15(d)

FEDERAL DEPOSIT INSURANCE CORPORATION. Washington, D.C FORM 8-K CURRENT REPORT. PURSUANT TO SECTION 13 OR 15(d) FEDERAL DEPOSIT INSURANCE CORPORATION Washington, D.C. 20429 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):

More information

VISA INC. FORM 8-K. (Current report filing) Filed 02/27/15 for the Period Ending 02/27/15

VISA INC. FORM 8-K. (Current report filing) Filed 02/27/15 for the Period Ending 02/27/15 FORM 8-K (Current report filing) Filed 02/27/15 for the Period Ending 02/27/15 Address P.O. BOX 8999 SAN FRANCISCO, CA 94128-8999 Telephone (415) 932-2100 CIK 0001403161 Symbol V SIC Code 7389 - Business

More information

HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter)

HTG Molecular Diagnostics, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

JACOBS ENGINEERING GROUP INC /DE/

JACOBS ENGINEERING GROUP INC /DE/ JACOBS ENGINEERING GROUP INC /DE/ FORM 8-K (Current report filing) Filed 04/29/14 for the Period Ending 04/28/14 Address 155 NORTH LAKE AVENUE PASADENA, CA 91101 Telephone 6265783500 CIK 0000052988 Symbol

More information

HORIZON PHARMA PLC FORM 8-K. (Current report filing) Filed 05/19/16 for the Period Ending 05/18/16

HORIZON PHARMA PLC FORM 8-K. (Current report filing) Filed 05/19/16 for the Period Ending 05/18/16 HORIZON PHARMA PLC FORM 8-K (Current report filing) Filed 05/19/16 for the Period Ending 05/18/16 Telephone 011-353-1-772-2100 CIK 0001492426 Symbol HZNP SIC Code 2834 - Pharmaceutical Preparations Industry

More information

GULFPORT ENERGY CORPORATION

GULFPORT ENERGY CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities exchange act of 1934 Date of report (Date of earliest event

More information

EDWARDS LIFESCIENCES CORP

EDWARDS LIFESCIENCES CORP EDWARDS LIFESCIENCES CORP FORM 8-K (Current report filing) Filed 11/14/14 for the Period Ending 11/13/14 Address ONE EDWARDS WAY IRVINE, CA 92614 Telephone 9492502500 CIK 0001099800 Symbol EW SIC Code

More information

COSTCO WHOLESALE CORPORATION (Exact name of registrant as specified in its charter)

COSTCO WHOLESALE CORPORATION (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

INFOSPACE INC FORM 8-K. (Current report filing) Filed 12/21/06 for the Period Ending 12/21/06

INFOSPACE INC FORM 8-K. (Current report filing) Filed 12/21/06 for the Period Ending 12/21/06 INFOSPACE INC FORM 8-K (Current report filing) Filed 12/21/06 for the Period Ending 12/21/06 Address 601 108TH AVE NE SUITE 1200 BELLEVUE, WA 98004 Telephone 4258821602 CIK 0001068875 Symbol INSP SIC Code

More information

INTERNATIONAL BANCSHARES CORPORATION (Exact Name of registrant as specified in its charter)

INTERNATIONAL BANCSHARES CORPORATION (Exact Name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest

More information

XENOPORT INC FORM 8-K. (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14

XENOPORT INC FORM 8-K. (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14 XENOPORT INC FORM 8-K (Current report filing) Filed 05/08/14 for the Period Ending 05/08/14 Address 3410 CENTRAL EXPRESSWAY SANTA CLARA, CA 95051 Telephone 4086167200 CIK 0001130591 Symbol XNPT SIC Code

More information

TIME WARNER CABLE INC. (TWC) 8-K. Current report filing Filed on 03/13/2009 Filed Period 03/12/2009

TIME WARNER CABLE INC. (TWC) 8-K. Current report filing Filed on 03/13/2009 Filed Period 03/12/2009 TIME WARNER CABLE INC. (TWC) 8-K Current report filing Filed on 03/13/2009 Filed Period 03/12/2009 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

BRIDGEPOINT EDUCATION INC

BRIDGEPOINT EDUCATION INC BRIDGEPOINT EDUCATION INC FORM 8-K (Current report filing) Filed 11/12/13 for the Period Ending 11/08/13 Address 13500 EVENING CREEK DR. #600 SAN DIEGO, CA 92128 Telephone 858-668-2586 CIK 0001305323 Symbol

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

VIRGINIA (State or other jurisdiction of incorporation) 500 Volvo Parkway Chesapeake, VA (Address of principal executive offices)

VIRGINIA (State or other jurisdiction of incorporation) 500 Volvo Parkway Chesapeake, VA (Address of principal executive offices) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event

More information

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported:

More information

Ladenburg Thalmann Financial Services Inc.

Ladenburg Thalmann Financial Services Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

STEINWAY MUSICAL INSTRUMENTS INC

STEINWAY MUSICAL INSTRUMENTS INC STEINWAY MUSICAL INSTRUMENTS INC FORM 8-K (Current report filing) Filed 12/26/12 for the Period Ending 12/20/12 Address 800 SOUTH STREET SUITE 305 WALTHAM, MA 02453-1472 Telephone 7818949770 CIK 0000911583

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

QUALCOMM INC/DE FORM 8-K. (Current report filing) Filed 09/30/15 for the Period Ending 09/28/15

QUALCOMM INC/DE FORM 8-K. (Current report filing) Filed 09/30/15 for the Period Ending 09/28/15 QUALCOMM INC/DE FORM 8-K (Current report filing) Filed 09/30/15 for the Period Ending 09/28/15 Address 5775 MOREHOUSE DR SAN DIEGO, CA 92121 Telephone 8585871121 CIK 0000804328 Symbol QCOM SIC Code 3663

More information

SECURITIES AND EXCHANGE COMMISSION FORM 8-K GENSPERA, INC.

SECURITIES AND EXCHANGE COMMISSION FORM 8-K GENSPERA, INC. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):

More information

JER INVESTORS TRUST INC (JERT) 8-K. Current report filing Filed on 04/11/2007 Filed Period 04/11/2007

JER INVESTORS TRUST INC (JERT) 8-K. Current report filing Filed on 04/11/2007 Filed Period 04/11/2007 JER INVESTORS TRUST INC (JERT) 8-K Current report filing Filed on 04/11/2007 Filed Period 04/11/2007 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

Illumina, Inc. (Exact name of registrant as specified in its charter)

Illumina, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

STARZ FORM 8-K. (Current report filing) Filed 06/27/16 for the Period Ending 06/16/16

STARZ FORM 8-K. (Current report filing) Filed 06/27/16 for the Period Ending 06/16/16 STARZ FORM 8-K (Current report filing) Filed 06/27/16 for the Period Ending 06/16/16 Address 8900 LIBERTY CIRCLE ENGLEWOOD, CO 80112 Telephone (720) 852-7700 CIK 0001507934 Symbol STRZA SIC Code 4841 -

More information

AMERUS GROUP CO/IA. FORM 8-K (Current report filing) Filed 8/15/2006 For Period Ending 8/14/2006

AMERUS GROUP CO/IA. FORM 8-K (Current report filing) Filed 8/15/2006 For Period Ending 8/14/2006 AMERUS GROUP CO/IA FORM 8-K (Current report filing) Filed 8/15/2006 For Period Ending 8/14/2006 Address 699 WALNUT STREET DES MOINES, Iowa 50309 Telephone 515-362-3600 CIK 0001051717 Industry Insurance

More information

American Electric Technologies Inc

American Electric Technologies Inc SECURITIES & EXCHANGE COMMISSION EDGAR FILING American Electric Technologies Inc Form: 8-K Date Filed: 2015-11-16 Corporate Issuer CIK: 1043186 Copyright 2015, Issuer Direct Corporation. All Right Reserved.

More information

Morningstar Document Research

Morningstar Document Research Morningstar Document Research FORM8-K PAYCHEX INC - PAYX Filed: March 25, 2015 (period: March 25, 2015) Report of unscheduled material events or corporate changes. The information contained herein may

More information

Form 8-K. Current Report. Caterpillar Financial Services Corporation

Form 8-K. Current Report. Caterpillar Financial Services Corporation UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

DELTA TUCKER HOLDINGS, INC.

DELTA TUCKER HOLDINGS, INC. DELTA TUCKER HOLDINGS, INC. FORM 8-K (Current report filing) Filed 10/30/14 for the Period Ending 10/30/14 Address 13601 NORTH FREEWAY, SUITE 200 FORT WORTH, TX 76177 Telephone 571-722-0210 CIK 0001514226

More information

CHINA BIOLOGIC PRODUCTS, INC.

CHINA BIOLOGIC PRODUCTS, INC. CHINA BIOLOGIC PRODUCTS, INC. FORM 8-K (Current report filing) Filed 04/25/12 for the Period Ending 04/25/12 Telephone 86-10-6598-3111 CIK 0001369868 Symbol CBPO SIC Code 2836 - Biological Products, Except

More information

Integral Technologies, Inc. (Exact name of registrant as specified in its charter)

Integral Technologies, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

HERCULES TECHNOLOGY GROWTH CAPITAL INC

HERCULES TECHNOLOGY GROWTH CAPITAL INC HERCULES TECHNOLOGY GROWTH CAPITAL INC FORM 8-K (Current report filing) Filed 10/2/2006 For Period Ending 10/2/2006 Address 525 UNIVERSITY AVE. SUITE 700 PALO ALTO, California 94301 Telephone 650-798-5164

More information

IMS HEALTH HOLDINGS, INC.

IMS HEALTH HOLDINGS, INC. IMS HEALTH HOLDINGS, INC. FORM 8-K (Current report filing) Filed 06/30/14 for the Period Ending 06/30/14 Address 83 WOOSTER HEIGHTS ROAD DANBURY, CT 06810 Telephone 203-448-4600 CIK 0001595262 Symbol IMS

More information

GLOBAL DEFENSE & NATIONAL SECURITY SYSTEMS, INC.

GLOBAL DEFENSE & NATIONAL SECURITY SYSTEMS, INC. GLOBAL DEFENSE & NATIONAL SECURITY SYSTEMS, INC. FORM DEFA14A (Additional Proxy Soliciting Materials (definitive)) Filed 07/14/15 Address 11921 FREEDOM DRIVE, SUITE 550 TWO FOUNTAIN SQUARE RESTON, VA 20190

More information

FEDERAL DEPOSIT INSURANCE CORPORATION Washington, D.C. 20429 FORM 8-K. Summit State Bank (Exact name of registrant as specified in its charter)

FEDERAL DEPOSIT INSURANCE CORPORATION Washington, D.C. 20429 FORM 8-K. Summit State Bank (Exact name of registrant as specified in its charter) FEDERAL DEPOSIT INSURANCE CORPORATION Washington, D.C. 20429 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):

More information

eon Communications Corporation

eon Communications Corporation UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

CAREER EDUCATION CORP (CECO) 8-K. Current report filing Filed on 06/12/2012 Filed Period 06/07/2012

CAREER EDUCATION CORP (CECO) 8-K. Current report filing Filed on 06/12/2012 Filed Period 06/07/2012 CAREER EDUCATION CORP (CECO) 8-K Current report filing Filed on 06/12/2012 Filed Period 06/07/2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant

More information

UNITED STATES. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K

UNITED STATES. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Page 1 of 10 8-K 1 a8k06022014.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of

More information

INCONTACT, INC. FORM 8-K. (Current report filing) Filed 03/25/15 for the Period Ending 03/23/15

INCONTACT, INC. FORM 8-K. (Current report filing) Filed 03/25/15 for the Period Ending 03/23/15 INCONTACT, INC. FORM 8-K (Current report filing) Filed 03/25/15 for the Period Ending 03/23/15 Address 7730 S. UNION PARK AVE., SUITE 500 NONE MIDVALE, UT 84047 Telephone (801) 320-3300 CIK 0001087934

More information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event

More information

HONG KONG HIGHPOWER TECHNOLOGY, INC.

HONG KONG HIGHPOWER TECHNOLOGY, INC. HONG KONG HIGHPOWER TECHNOLOGY, INC. FORM 8-K (Current report filing) Filed 01/28/09 for the Period Ending 01/28/09 Telephone 86 755 896 86238 CIK 0001368308 Symbol HPJ SIC Code 3690 - Miscellaneous Electrical

More information

STURM, RUGER & COMPANY, INC. (Exact Name of Registrant as Specified in its Charter)

STURM, RUGER & COMPANY, INC. (Exact Name of Registrant as Specified in its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

GARDNER DENVER INC FORM 8-K. (Current report filing) Filed 11/19/12 for the Period Ending 11/12/12

GARDNER DENVER INC FORM 8-K. (Current report filing) Filed 11/19/12 for the Period Ending 11/12/12 GARDNER DENVER INC FORM 8-K (Current report filing) Filed 11/19/12 for the Period Ending 11/12/12 Address 1500 LIBERTY RIDGE DRIVE, SUITE 3000 WAYNE, PA 19087 Telephone 6102492000 CIK 0000916459 SIC Code

More information

THE GOLDMAN SACHS GROUP, INC. (Exact name of registrant as specified in its charter)

THE GOLDMAN SACHS GROUP, INC. (Exact name of registrant as specified in its charter) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date

More information

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT May 24, 2012 (Date of Earliest Event

More information

FORM 8-K. CREATIVE REALITIES, INC. (Exact name of registrant as specified in its charter)

FORM 8-K. CREATIVE REALITIES, INC. (Exact name of registrant as specified in its charter) 8-K 1 f8k091514_creativerealities.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE

More information

FEDERATED NATIONAL HOLDING COMPANY (Exact name of registrant as specified in its charter)

FEDERATED NATIONAL HOLDING COMPANY (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 9, 2014 (Date

More information

National American University Holdings, Inc.

National American University Holdings, Inc. SECURITIES & EXCHANGE COMMISSION EDGAR FILING National American University Holdings, Inc. Form: 8-K Date Filed: 2015-08-13 Corporate Issuer CIK: 1399855 Copyright 2015, Issuer Direct Corporation. All Right

More information

TIME WARNER INC. FORM 8-K. (Current report filing) Filed 11/09/07 for the Period Ending 11/05/07

TIME WARNER INC. FORM 8-K. (Current report filing) Filed 11/09/07 for the Period Ending 11/05/07 TIME WARNER INC. FORM 8-K (Current report filing) Filed 11/09/07 for the Period Ending 11/05/07 Address ONE TIME WARNER CENTER NEW YORK, NY 10019 Telephone 2124848000 CIK 0001105705 Symbol TWX SIC Code

More information

SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT. Date of Report (Date of earliest event reported): May 5, 2016

SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT. Date of Report (Date of earliest event reported): May 5, 2016 IPCC 8-K 5/5/2016 Section 1: 8-K (8-K) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report

More information

Victory Energy Corporation (Exact name of registrant as specified in its charter)

Victory Energy Corporation (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

HOME LOAN SERVICING SOLUTIONS, LTD.

HOME LOAN SERVICING SOLUTIONS, LTD. HOME LOAN SERVICING SOLUTIONS, LTD. FORM DEFA14A (Additional Proxy Soliciting Materials (definitive)) Filed 04/24/15 Telephone (345) 945-3727 CIK 0001513161 Symbol HLSS SIC Code 6162 - Mortgage Bankers

More information

PLAINS ALL AMERICAN PIPELINE LP

PLAINS ALL AMERICAN PIPELINE LP PLAINS ALL AMERICAN PIPELINE LP FORM 8-K (Current report filing) Filed 01/09/15 for the Period Ending 01/09/15 Address 333 CLAY STREET SUITE 1600 HOUSTON, TX 77002 Telephone 7136544100 CIK 0001070423 Symbol

More information

AMERISAFE INC FORM 8-K. (Current report filing) Filed 04/29/15 for the Period Ending 04/29/15

AMERISAFE INC FORM 8-K. (Current report filing) Filed 04/29/15 for the Period Ending 04/29/15 AMERISAFE INC FORM 8-K (Current report filing) Filed 04/29/15 for the Period Ending 04/29/15 Address 2301 HIGHWAY 190 WEST DERIDDER, LA 70634 Telephone 337-463-9052 CIK 0001018979 Symbol AMSF SIC Code

More information

PRICE T ROWE GROUP INC

PRICE T ROWE GROUP INC PRICE T ROWE GROUP INC FORM 8-K (Current report filing) Filed 09/10/15 for the Period Ending 09/10/15 Address 100 EAST PRATT STREET P.O. BOX 89000 BALTIMORE, MD 21289-0320 Telephone 4103452000 CIK 0001113169

More information

LOJACK CORP FORM 8-K. (Current report filing) Filed 10/19/12 for the Period Ending 10/18/12

LOJACK CORP FORM 8-K. (Current report filing) Filed 10/19/12 for the Period Ending 10/18/12 LOJACK CORP FORM 8-K (Current report filing) Filed 10/19/12 for the Period Ending 10/18/12 Address 40 PEQUOT WAY CANTON, MA 02021 Telephone 781-302-4200 CIK 0000355777 Symbol LOJN SIC Code 3669 - Communications

More information